United States

Regulus Therapeutics Inc (RGLS.OQ)

RGLS.OQ on NASDAQ Stock Exchange Global Market

20 Oct 2017
Change (% chg)

$-0.04 (-3.20%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Regulus Therapeutics Q2 loss per share $0.41
Tuesday, 1 Aug 2017 04:10pm EDT 

Aug 1 (Reuters) - Regulus Therapeutics Inc :Regulus reports second quarter 2017 financial results and recent events.Q2 revenue $100,000.Q2 revenue view $873,000 -- Thomson Reuters I/B/E/S.Q2 loss per share $0.41.Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Broadfin Capital reports 5.65 pct passive stake in Regulus Therapeutics - ‍​SEC filing
Monday, 24 Jul 2017 11:24am EDT 

July 24 (Reuters) - Broadfin Capital LLC::Broadfin Capital LLC reports 5.65 percent passive stake in Regulus Therapeutics Inc as of July 20, 2017 - ‍​SEC filing.  Full Article

Regulus Therapeutics prices offering of 44 mln shares at $0.91 per share
Wednesday, 19 Jul 2017 09:45pm EDT 

July 19 (Reuters) - Regulus Therapeutics Inc ::Regulus announces pricing of public offering of common stock.Says public offering of 44.0 million common shares priced at $0.91 per share.  Full Article

Regulus says plans to discontinue clinical development of RG-101
Monday, 12 Jun 2017 07:00am EDT 

June 12 (Reuters) - Regulus Therapeutics Inc :Regulus announces pipeline updates and advancements.Regulus -plans to discontinue clinical development of rg-101 upon completion of one remaining clinical study, which is expected to occur in july 2017.Regulus therapeutics inc says initiation of phase ii clinical programs for rg-012 for treatment of alport syndrome is on track as planned.Regulus therapeutics inc says data from renal biopsy study is anticipated by year-end and interim data from hera is anticipated mid-2018.Regulus -evaluation of clinical data led to identification of a bilirubin transport mechanism as likely cause for cases of hyperbilirubinemia in rg-101 program.Regulus therapeutics inc says ind for rgls4326 is on track for filing by year end 2017.Regulus - astrazeneca informed co that it intends to terminate clinical development program for azd4076 for treatment of nash in type 2 diabetes/pre-diabetes.Regulus -under agreement, astrazeneca's rights with respect to azd4076(rg-125) will revert to regulus when termination becomes effective in twelve months.  Full Article

EcoR1 Capital reports 9.6 pct passive stake in Regulus Therapeutics
Tuesday, 30 May 2017 05:28pm EDT 

May 30 (Reuters) - Regulus Therapeutics Inc :EcoR1 Capital LLLC reports a 9.6 percent passive stake in Regulus Therapeutics Inc as of May 17 - SEC filing.  Full Article

Regulus reports Q1 revenue $100,000
Thursday, 4 May 2017 04:30pm EDT 

May 4 (Reuters) - Regulus Therapeutics Inc :Regulus reports first quarter 2017 financial results and corporate restructuring.Q1 loss per share $0.38.Q1 revenue $100,000 versus $500,000.Q1 revenue view $944,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Regulus Therapeutics Inc says Paul Grint, president and CEO, to resign.Regulus Therapeutics Inc - Announced a corporate restructuring plan to streamline its operations.Regulus Therapeutics Inc says to restructure operations accompanied by a workforce reduction.Says cutting workforce by about 30 percent.Regulus Therapeutics Inc - Restructuring includes an immediate workforce reduction of approximately 30%.Regulus Therapeutics Inc says restructuring expected to result in approximately $6.0 million in annual savings after one-time restructuring costs.Regulus Therapeutics Inc - Promoted Daniel R. Chevallard to position of chief financial officer, effective immediately.Regulus Therapeutics Inc says Jay Hagan to succeed Paul Grint as CEO.  Full Article

Regulus reports Q4 loss per share $0.38
Thursday, 2 Mar 2017 04:10pm EST 

Regulus Therapeutics Inc : Regulus reports fourth quarter 2016 financial results and pipeline update . Q4 loss per share $0.38 . Q4 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S . Qtrly revenue was less than $0.1 million, compared to $10.9 million . Q4 revenue view $917430.00 -- Thomson Reuters I/B/E/S . Has modified PHASE II rg-012 clinical development program in patients with alport syndrome . Regulus Therapeutics - Phase II Rg-012 program will include hera study, a 48-week study in 30 patients with rapid renal function decline .Regulus Therapeutics - hera study objective is to evaluate safety, efficacy of RG-012 for treating renal function decline in patients with alport syndrome.  Full Article

Regulus Therapeutics announces continuation of RG-101 clinical hold
Friday, 27 Jan 2017 04:10pm EST 

Regulus Therapeutics Inc : Regulus announces continuation of RG-101 clinical hold . Received written communication from FDA that clinical development program for RG-101 remains on clinical hold . FDA also requested additional expert review of liver safety data in light of proposed mechanism of hyperbilirubinemia . We plan to continue to work with FDA to address their additional requests as we seek removal of clinical hold of RG-101 . FDA has requested final safety, efficacy data from on-going RG-101 clinical and pre-clinical studies before reconsidering clinical hold .Data from RG-101 trial is anticipated in q4.  Full Article

Regulus Therapeutics q2 loss per share $0.40
Tuesday, 2 Aug 2016 04:10pm EDT 

Regulus Therapeutics Inc : Q2 loss per share $0.40 . On track to deliver follow-up results from rg-101 studies while working to address deficiencies outlined in by fda . Qtrly revenue was $0.5 million compared with $3.8 million .Initiating a phase ii study in alport syndrome for rg-012, and plan to nominate our fourth clinical candidate by year-end.  Full Article

Regulus says working to resolve issues outlined in letter from US FDA about clinical hold
Wednesday, 27 Jul 2016 04:10pm EDT 

Regulus Therapeutics Inc : Received written communication from u.s. FDA outlining information required to resolve clinical hold for its IND for RG-101 . Says On Track To Deliver Follow Up results from on-going RG-101 studies . Working to resolve issues outlined in letter and anticipate a decision from FDA in q4 . "we remain on track to deliver follow-up results from ongoing rg-101 studies" . Fda requested detailed safety data analysis from preclinical and clinical studies among other things . Fda will notify regulus of its decision within 30 days of receipt of complete response to issues .Timelines of on-going studies have not been impacted by clinical hold.  Full Article

BRIEF-Growth Equity Opportunities reports 11.3 pct stake in Regulus Therapeutics

* Growth Equity Opportunities V reports 11.3 percent stake in Regulus Therapeutics Inc as of July 24 - SEC filing Source text: (http://bit.ly/2u4yxoS) Further company coverage: